Charles River Laboratories
251 Ballardvale Street
About Charles River Laboratories
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.
For more information, please visit www.criver.com.
Equal Employment Opportunity
Charles River Laboratories, Inc. is an Equal Opportunity Employer M/F/Disabled/Vet
335 articles with Charles River Laboratories
Access to Resero’s TurboToxicology™ will provide faster delivery of high-quality toxicology reports
Charles River Laboratories International, Inc. reported its results for the first quarter of 2019.
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.
The company disclosed the data breach in a filing with the U.S. Securities and Exchange Commission on Tuesday. The hacking occurred in March and the company said the data of about 1 percent of its total number of clients was compromised.
Charles River Laboratories International, Inc. announced that it has completed the previously announced acquisition of Citoxlab for €448 million in cash, subject to customary closing adjustments.
A conference call has been scheduled to discuss this information on Tuesday, May 7th, at 8:30 a.m. ET.
Behind every patient stands thousands of scientists and researchers collaborating to develop life-saving drugs. Jenne’s story highlights the importance of that work.
More job cuts are coming to California life science companies. Charles River Labs and Janssen are both making cuts as they reprioritize their businesses, according to Worker Adjustment and Retraining Notifications filed with the state of California.
Researchers will highlight work in BRCA-deficient and rare pediatric cancers
Management will present an overview of Charles River’s strategic focus and business developments.
Charles River Laboratories International, Inc. announced that it has signed a binding offer to acquire Citoxlab for €448 million in cash, subject to customary closing adjustments.
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2018 Results and Provides 2019 Guidance
Charles River Laboratories International, Inc. reported its results for the fourth-quarter and full-year 2018 and provided guidance for 2019.
Charles River Laboratories Schedules Fourth-Quarter 2018 Earnings and 2019 Guidance Release and Conference Call
A conference call has been scheduled to discuss this information on Wednesday, February 13th, at 8:30 a.m. ET.
The 2019 Gender-Equality Index highlights 230 firms that are trailblazers in their commitment to gender diversity in the workplace
Charles River Laboratories and Atomwise Form a Strategic Alliance to Provide Integrated, Artificial Intelligence-Driven Drug Discovery
Charles River reaffirms commitment to the future of drug discovery by advancing the Company’s integrated, innovative early-stage platform
Atomwise and Charles River Laboratories Form a Strategic Alliance to Provide Premier Artificial Intelligence-Powered Drug Discovery Capabilities
Charles River’s clients gain access to Atomwise’s Artificial Intelligence (AI) technology to improve novelty, quality and efficiency of preclinical drug discovery.
As 2019 gets underway for the biopharma industry, more companies are increasing their reliance on the use of artificial intelligence as part of their drug discovery process.
Charles River Laboratories International, Inc. announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 8th, at 10:00 a.m. PST (1:00 p.m. EST)
After enduring a deluge from multiple hurricanes earlier this year, the Carolinas are about to be flooded with something else far more preferable – jobs. Pharma companies are hiring for hundreds of positions, according to reports.
Seven African American seek unspecified damages over allegations of discrimination at Charleston, S.C. facility.